LLY ▲ +1.7% - Eli Lilly and Company $LLY - Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health Eli Lilly rose 1.7% today following an announcement that the company will present new data on three key programs—Foundayo, retatrutide, and eloraTZP—at the European Association for the Study of Diabetes (EASD) 2026 conference. The presentation of additional clinical data on these cardiometabolic and diabetes candidates signals continued progress in Lilly's pipeline in a high-priority therapeutic area. 15-SEP-2026 06:46 AM ET